CV-01
Phase 1Candidate aimed at drug-resistant epilepsy and other conditions; partner Angelini Pharma received approval in Sweden in June 2026 for a 36-person Phase 1 trial.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Its two small-molecule candidates are cleared for Phase 1 trials in the US and Europe, and it passed the KOSDAQ technology evaluation.
Roles often seen at this stageClinical & PV · Research & development · BD & licensing
Develops small-molecule drugs for brain diseases and granted Italy's Angelini Pharma a global license option on its candidate CV-01.
Candidate aimed at drug-resistant epilepsy and other conditions; partner Angelini Pharma received approval in Sweden in June 2026 for a 36-person Phase 1 trial.
Small-molecule candidate acting selectively on the S1P1 receptor; cleared by the US FDA for a Phase 1 trial in 64 healthy adults.
Received A and A grades from two agencies in its KOSDAQ technology evaluation.
A Phase 1 trial of CV-01 was approved in Sweden.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.